Please login to the form below

Not currently logged in
Email:
Password:

Robert Freisen joins Ablynx

He will take the role of chief scientific officer, effective March 1

Ablynx, recently acquired by Sanofi, has appointed Robert Freisen to the role of chief scientific officer, who will head the biopharma’s scientific research and technology activities.

He succeeds Dr Antonin de Fougerolles, who left the company last year to become Evox Therapeutics’ chief executive officer.

Freisen has more than 20 years’ experience in the biopharmaceutical industry, leading multiple research and development organisations.

He said: “I have long admired Ablynx and am excited to join the company at such an important time.

“With Ablynx's strong pipeline, platform and technology, I am confident that our talented team will continue to deliver novel products to patients that address unmet medical needs where there are currently limited or no therapeutic options."

He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.

Dr Edwin Moses, chief executive officer of Ablynx, said: “Robert brings an extensive track record of successfully initiating and executing new drug discovery programmes as well as building strong research organisations.

“We are pleased to have him join our team and lead our company's research activities at such an important and exciting time for Ablynx and we will be able to leverage his critical expertise and proven leadership capabilities as we expand our proprietary Nanobody product pipeline.”

31st January 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics